Skip to main content

Breast Cancer

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

First-Line Pembrolizumab plus Chemotherapy Extend Progression-Free Survival in Patients with Metastatic Triple-Negative Breast Cancer

Phoebe Starr

Breast Cancer, FDA Approvals, Select Drug Profiles

Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer

Less May Be “More” with Zoledronic Acid

Caroline Helwick

MONALEESA-7 Sets New Standard of Care for Premenopausal Advanced Breast Cancer: Adding CDK4/6 to Endocrine Therapy Extends Survival

Phoebe Starr

New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer

No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer

Phoebe Starr

1
2
3

Page 2 of 3
Results 11 - 20 of 29